

# Joseph J Eron

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4759541/joseph-j-eron-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

368  
papers

32,800  
citations

84  
h-index

176  
g-index

384  
ext. papers

37,123  
ext. citations

8.8  
avg, IF

6.36  
L-index

#	Paper	IF	Citations
368	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.. <i>Aids</i> , <b>2022</b> , 36, 277-286	3.5	2
367	Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2022</b> , 12, 757846	5.9	0
366	A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.. <i>Science Translational Medicine</i> , <b>2021</b> , 14, eab17430	17.5	48
365	Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project.. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25846	5.4	1
364	Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	2
363	Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e643-e651	11.6	1
362	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e2334-e2337	11.6	4
361	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 92-100	7	9
360	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 657-666	7	1
359	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005-2015. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 2113-2123	7	5
358	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1408-e1414	11.6	3
357	Fusion designs and estimators for treatment effects. <i>Statistics in Medicine</i> , <b>2021</b> , 40, 3124-3137	2.3	2
356	Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 86, 339-343	3.1	12
355	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005-2015. <i>Aids</i> , <b>2021</b> , 35, 1229-1239	3.5	
354	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , <b>2021</b> , 35, 1585-1595	3.5	3
353	Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1717-1721	11.6	8
352	Short-cycle therapy is short on ethics. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 57, 106331	14.3	

351	Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates <b>2021</b> ,		1
350	Comparison of methods to quantify inducible HIV-1 outgrowth. <i>Journal of Virus Eradication</i> , <b>2021</b> , 7, 100043	0.43	1
349	HIV-1 Transmission linkages among persons with incident infection to inform public health surveillance. <i>EClinicalMedicine</i> , <b>2021</b> , 37, 100968	11.3	0
348	Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 462-470	7	1
347	and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection: A Case Report and Review of an Emerging Diagnostic Dilemma. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa633	1	14
346	Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1093-1100	11.6	2
345	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 225-233	7	24
344	Opioid misuse among persons with HIV engaged in care in the Southeastern US. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 33, 148-153	2.2	2
343	HIV Viremia and Risk of Stroke Among People Living with HIV Who Are Using Antiretroviral Therapy. <i>Epidemiology</i> , <b>2021</b> , 32, 457-464	3.1	2
342	HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	9
341	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 595-608	59.2	48
340	Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study. <i>Medicine (United States)</i> , <b>2021</b> , 100, e26817	1.8	0
339	Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic. <i>Healthcare</i> , <b>2021</b> , 9, 100581	1.8	0
338	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population : An Observational Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1197-1206	8	3
337	Drug and alcohol use among people living with HIV in care in the United States by geographic region. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2021</b> , 33, 1569-1576	2.2	4
336	Genetic architecture of cardiometabolic risks in people living with HIV. <i>BMC Medicine</i> , <b>2020</b> , 18, 288	11.4	2
335	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. <i>BMJ Open</i> , <b>2020</b> , 10, e031487	3	1
334	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 1843-1852	7	9

333	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , <b>2020</b> , 10, 5134	4.9	13
332	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , <b>2020</b> , 181, 189-206	56.2	48
331	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e472-e481	7.8	32
330	Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008-2015. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 170-177	8.5	6
329	Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228847	3.7	14
328	Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, 60-65	3.1	3
327	Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women's Interagency HIV Study. <i>AIDS and Behavior</i> , <b>2020</b> , 24, 2033-2044	4.3	2
326	Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , <b>2020</b> , 34, 707-718	3.5	16
325	T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. <i>Aids</i> , <b>2020</b> , 34, 15-24	3.5	11
324	Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. <i>Aids</i> , <b>2020</b> , 34, 1923-1931	3.5	3
323	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1651-1669	27.4	128
322	Estimating a Set of Mortality Risk Functions with Multiple Contributing Causes of Death. <i>Epidemiology</i> , <b>2020</b> , 31, 704-712	3.1	1
321	Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 319-322	11.6	15
320	Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 1131-1138	11.6	20
319	Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 867-874	11.6	8
318	Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996-2016. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1616-1623	11.6	13
317	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. <i>AIDS Research and Therapy</i> , <b>2019</b> , 16, 23	3	5
316	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. <i>Aids</i> , <b>2019</b> , 33, 1455-1465	3.5	60

315	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e93-e104	7.8	58
314	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , <b>2019</b> , 12, 302-311	4.9	2
313	Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 291-300	1.6	0
312	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e240-e249	7.8	25
311	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e259-e268	7.8	87
310	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , <b>2019</b> , 38, 2428-2446	2.3	10
309	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with	10.8	19
308	Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS). <i>BMC Medicine</i> , <b>2019</b> , 17, 149	11.4	14
307	Clones of infected cells arise early in HIV-infected individuals. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	35
306	Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 3339-3346	15.9	48
305	Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, e141-e147	3.1	6
304	Postpartum HIV care continuum outcomes in the southeastern USA. <i>Aids</i> , <b>2019</b> , 33, 637-644	3.5	6
303	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. <i>Epidemiology</i> , <b>2019</b> , 30, 358-364	3.1	4
302	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 572-577	3.1	9
301	Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 81, 594-599	3.1	8
300	Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 82, e27-e31	3.1	11
299	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1345-1352	11.6	33
298	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , <b>2019</b> , 393, 148-155	40	175

297	Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofy341	1	3
296	Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials. <i>Aids</i> , <b>2018</b> , 32, 1053-1057	3.5	1
295	Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 1808-1816	3.8	5
294	Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>2018</b> , 181, 1193-1209	2.1	45
293	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 234-238	7	14
292	Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate. <i>AIDS Research and Human Retroviruses</i> , <b>2018</b> , 34, 481-485	1.6	
291	Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 363-372	1.6	6
290	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 78, 62-72	3.1	37
289	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, 484-491	3.1	5
288	Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. <i>AIDS and Behavior</i> , <b>2018</b> , 22, 742-751	4.3	21
287	Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. <i>AIDS Research and Human Retroviruses</i> , <b>2018</b> , 34, 111-122	1.6	32
286	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomized, controlled, non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, 22-34	7.8	64
285	Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. <i>Biometrical Journal</i> , <b>2018</b> , 60, 100-114	1.5	1
284	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 379-396	27.4	390
283	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. <i>AIDS Research and Human Retroviruses</i> , <b>2018</b> , 34, 916-921	1.6	0
282	Comparing neighborhood and state contexts for women living with and without HIV: understanding the Southern HIV epidemic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2018</b> , 30, 1360-1367	2.2	6
281	Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197665	3.7	5
280	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 376-384	8	67

279	T cells establish and maintain CNS viral infection in HIV-infected humanized mice. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2862-2876	15.9	25
278	Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. <i>Lancet HIV,the</i> , <b>2018</b> ,	7.8	16
277	Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. <i>Aids</i> , <b>2018</b> , 32, 261-266	3.5	8
276	Leveraging Phylogenetics to Understand HIV Transmission and Partner Notification Networks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 78, 367-375	3.1	14
275	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002690	11.6	74
274	1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/FTD) in Virologically Suppressed HIV-1-Infected Adults: Week 96 Results of the Phase 3,	1	1
273	HIV-Specific, ExVivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , <b>2018</b> , 26, 2496-2506	11.7	18
272	Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy242	1	17
271	Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy178	1	13
270	Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 316-325	3.8	9
269	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , <b>2018</b> , 28, 179-187	1.9	4
268	Identifying HIV care enrollees at-risk for cannabis use disorder. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2017</b> , 29, 846-850	2.2	11
267	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 324-327	11.6	15
266	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e251-e259	7.8	9
265	Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 1591-1596	11.6	9
264	Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1725-1733	7	146
263	Brief Report: Longitudinal Opioid Use Among HIV-Infected Patients, 2000 to 2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 77-80	3.1	8
262	Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 75, 568-576	3.1	77

261	Virologic outcomes in early antiretroviral treatment: HPTN 052. <i>HIV Clinical Trials</i> , <b>2017</b> , 18, 100-109		18
260	Prevalence and Factors Associated with Hazardous Alcohol Use Among Persons Living with HIV Across the US in the Current Era of Antiretroviral Treatment. <i>AIDS and Behavior</i> , <b>2017</b> , 21, 1914-1925	4.3	75
259	Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 155-162	16.2	71
258	Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 260-267	16.2	41
257	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180843	3.7	6
256	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006285	7.6	99
255	Rising prevalence of non-B HIV-1 subtypes in North Carolina and evidence for local onward transmission. <i>Virus Evolution</i> , <b>2017</b> , 3, vex013	3.7	18
254	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <i>Lancet, The</i> , <b>2017</b> , 390, 1499-1510	40.2	297
253	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , <b>2017</b> , 4, e536-e546	7.8	67
252	Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2017</b> , 29, 177-184	2.2	7
251	Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV. <i>AIDS Research and Human Retroviruses</i> , <b>2017</b> , 33, 534-545	1.6	5
250	Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. <i>Aids</i> , <b>2017</b> , 31, 1989-1997	3.5	15
249	The Role of Current and Historical Alcohol Use in Hepatic Fibrosis Among HIV-Infected Individuals. <i>AIDS and Behavior</i> , <b>2017</b> , 21, 1878-1884	4.3	11
248	Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Without HIV. <i>Journal of Women's Health</i> , <b>2017</b> , 26, 1292-1301	3	2
247	Health Insurance Type and Control of Hypertension Among US Women Living With and Without HIV Infection in the Women's Interagency HIV Study. <i>American Journal of Hypertension</i> , <b>2017</b> , 30, 594-601	2.3	5
246	Co-trimoxazole Prophylaxis, Asymptomatic Malaria Parasitemia, and Infectious Morbidity in Human Immunodeficiency Virus-Exposed, Uninfected Infants in Malawi: The BAN Study. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 575-580	11.6	6
245	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 636-643	11.6	44
244	Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. <i>AIDS and Behavior</i> , <b>2017</b> , 21, 1138-1148	4.3	87



243	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 3126-3135	15.9	111
242	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006629	7.6	22
241	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 468-475	11.6	40
240	Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 556-60	7	35
239	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 830-9	59.2	889
238	Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir. <i>Aids</i> , <b>2016</b> , 30, 2091-7	3.5	6
237	HIV primary care providers--Screening, knowledge, attitudes and behaviors related to alcohol interventions. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 161, 59-66	4.9	34
236	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 2038-2049	7.8	24
235	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. <i>AIDS Research and Human Retroviruses</i> , <b>2016</b> , 32, 50-8	1.6	152
234	Antiretroviral activity and safety of once-daily etravirine in treatment-naïve HIV-infected adults: 48-week results. <i>Antiviral Therapy</i> , <b>2016</b> , 21, 55-64	1.6	6
233	Macrophages sustain HIV replication in vivo independently of T cells. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 1353-66	15.9	150
232	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 191-210	27.4	449
231	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. <i>Journal of Virology</i> , <b>2016</b> , 90, 6058-6070	6.6	52
230	The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 140-50	7.8	36
229	Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 242-8	11.6	30
228	Increased Cortical Cerebral Blood Flow in Asymptomatic Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2016</b> , 25, 1891-5	2.8	4
227	Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3276-83	2.2	24
226	Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain. <i>AIDS Research and Human Retroviruses</i> , <b>2015</b> , 31, 658-68	1.6	38

225	HIV Transmission Patterns Among Immigrant Latinos Illuminated by the Integration of Phylogenetic and Migration Data. <i>AIDS Research and Human Retroviruses</i> , <b>2015</b> , 31, 973-80	1.6	16
224	R5 Macrophage-Tropic HIV-1 in the Male Genital Tract. <i>Journal of Virology</i> , <b>2015</b> , 89, 10688-92	6.6	7
223	Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1189-95	11.6	31
222	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. <i>Lancet Infectious Diseases</i> , <b>2015</b> , 15, 1145-1155	25.5	152
221	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 1700-7	11.6	28
220	Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1223-31	27.4	263
219	The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis. <i>American Journal of Epidemiology</i> , <b>2015</b> , 181, 714-22	3.8	8
218	Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy. <i>American Journal of Epidemiology</i> , <b>2015</b> , 181, 238-45	3.8	34
217	Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1179-88	11.6	35
216	End-stage renal disease among HIV-infected adults in North America. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 941-9	11.6	112
215	Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 307-15	1.6	7
214	Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 73-6	1.6	6
213	Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv045	1	2
212	Evaluating the incident user design in the HIV population: incident use versus naive?. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 297-300	2.6	
211	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. <i>Liver International</i> , <b>2015</b> , 35, 1886-92	7.9	13
210	Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. <i>Medical Care</i> , <b>2015</b> , 53, e41-8	3.1	13
209	HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 908-17	8	11
208	Dynamic Visual Display of Treatment Response in HIV-Infected Adults. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, e1-4	11.6	4

207	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 212, 1361-5	7	252
206	Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. <i>HIV Clinical Trials</i> , <b>2015</b> , 16, 147-56		8
205	Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127950	9.7	23
204	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. <i>Lancet Infectious Diseases</i> , <b>2014</b> , 14, 281-90	25.5	345
203	Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 423-31	11.6	82
202	Beyond core indicators of retention in HIV care: missed clinic visits are independently associated with all-cause mortality. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1471-9	11.6	111
201	Large scale screening of human sera for HCV RNA and GBV-C RNA. <i>Journal of Medical Virology</i> , <b>2014</b> , 86, 473-7	19.7	13
200	Viral suppression in HIV studies: combining times to suppression and rebound. <i>Biometrics</i> , <b>2014</b> , 70, 441-88		6
199	Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 949-55	1.6	36
198	Moving forward in HIV-associated cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 876-80	2.2	33
197	Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 279-86	11.6	30
196	Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6079-92	5.9	28
195	Hepatic safety and tolerability of raltegravir among HIV patients coinfecting with hepatitis B and/or C. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 415-22	1.6	12
194	Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e90485	3.7	26
193	Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19500	5.4	13
192	African American race and HIV virological suppression: beyond disparities in clinic attendance. <i>American Journal of Epidemiology</i> , <b>2014</b> , 179, 1484-92	3.8	25
191	HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1599-606	11.6	34
190	Disparities in the quality of HIV care when using US Department of Health and Human Services indicators. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 58, 1185-9	11.6	60

189	Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. <i>Annals of Internal Medicine</i> , <b>2014</b> , 161, 1-10	8	137
188	The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 233-40	1.6	17
187	HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 728-35	7	191
186	Incident sexually transmitted infection as a biomarker for high-risk sexual behavior after diagnosis of acute HIV. <i>Sexually Transmitted Diseases</i> , <b>2014</b> , 41, 447-52	2.4	13
185	Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 410-25	27.4	384
184	Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). <i>Antiviral Therapy</i> , <b>2014</b> , 19, 69-78	1.6	7
183	Spatial epidemiology of recently acquired HIV infections across rural and urban areas of North Carolina. <i>PLoS ONE</i> , <b>2014</b> , 9, e88512	3.7	7
182	Loss to clinic and five-year mortality among HIV-infected antiretroviral therapy initiators. <i>PLoS ONE</i> , <b>2014</b> , 9, e102305	3.7	11
181	HIV cure strategies: how good must they be to improve on current antiretroviral therapy?. <i>PLoS ONE</i> , <b>2014</b> , 9, e113031	3.7	17
180	Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 574-80	1.6	8
179	Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 859-70	1.6	18
178	Acute HIV-1 infection in the Southeastern United States: a cohort study. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 121-8	1.6	31
177	Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 740-8	7	227
176	Short communication: lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 887-91	1.6	3
175	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases, The</i> , <b>2013</b> , 13, 587-96	25.5	101
174	HIV risk behaviors and sociodemographic features of HIV-infected Latinos residing in a new Latino settlement area in the Southeastern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2013</b> , 25, 1298-307	2.2	18
173	Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 756-64	11.6	85
172	Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1174-82	11.6	82

171	Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003484	7.6	112
170	Advances in antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , <b>2013</b> , 8, 341-9	4.2	28
169	Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 784-8	5.9	14
168	Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1221-9	9.7	111
167	Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 290-7	11.6	20
166	Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1857-61	5.1	15
165	Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times. <i>Biometrics</i> , <b>2013</b> , 69, 732-40	1.8	5
164	The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 652-7	1.6	7
163	Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 136-41	1.6	5
162	Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. <i>AIDS Research and Human Retroviruses</i> , <b>2013</b> , 29, 1068-74	1.6	65
161	Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 39-43	1.6	18
160	Unmasking Lymphoma Immune Reconstitution Inflammatory Syndrome Among HIV-Infected Individuals In The Center For AIDS Research Network Of Integrated Clinical Systems. <i>Blood</i> , <b>2013</b> , 122, 4331-4331	2.2	1
159	Paradoxical interpretations of noninferiority studies: violating the excluded middle. <i>Future Virology</i> , <b>2012</b> , 7, 1055-1063	2.4	5
158	Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095. <i>Journal of the American Statistical Association</i> , <b>2012</b> , 107, 542-554	2.8	10
157	Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. <i>Aging Cell</i> , <b>2012</b> , 11, 916-8	9.9	48
156	High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible?. <i>Cancer Epidemiology</i> , <b>2012</b> , 36, 263-9	2.8	9
155	Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 387-402	27.4	637
154	Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 9523-8	11.5	170

153	Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naïve HIV-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3101-6	5.9	81
152	CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. <i>Journal of Immunology</i> , <b>2012</b> , 188, 4289-96	5.3	43
151	Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 789-92	1.6	3
150	Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 798-805	1.6	15
149	HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 995-1000	5.9	13
148	Reply to pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial. <i>Aids</i> , <b>2012</b> , 26, 397-398	3.5	
147	No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 59, 229-35	3.1	87
146	The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. <i>PLoS ONE</i> , <b>2012</b> , 7, e34399	3.7	12
145	Attrition among human immunodeficiency virus (HIV)-infected patients initiating antiretroviral therapy in China, 2003-2010. <i>PLoS ONE</i> , <b>2012</b> , 7, e39414	3.7	29
144	Prevention of HIV-1 infection with early antiretroviral therapy. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 493-505	59.2	5157
143	Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1265-70	11.6	78
142	Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2011</b> , 11, 907-15	25.5	155
141	Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in sub-Saharan Africa: a simulation. <i>PLoS ONE</i> , <b>2011</b> , 6, e18527	3.7	24
140	Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. <i>PLoS ONE</i> , <b>2011</b> , 6, e19617	3.7	58
139	High clade C HIV-1 viremia: how did we get here and where are we going?. <i>Aids</i> , <b>2011</b> , 25, 1543-5	3.5	2
138	Splines for trend analysis and continuous confounder control. <i>Epidemiology</i> , <b>2011</b> , 22, 874-5	3.1	114
137	Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 432-9	2.6	12
136	Pilot study demonstrating effectiveness of targeted education to improve informed consent understanding in AIDS clinical trials. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2011</b> , 23, 1382-91	2.2	6

135	Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 515-20	7	83
134	Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 480-7	11.6	72
133	Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. <i>American Journal of Epidemiology</i> , <b>2011</b> , 174, 727-35	3.8	9
132	Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. <i>Journal of Virology</i> , <b>2011</b> , 85, 5220-3	6.6	72
131	Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 927-35	11.6	103
130	Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 893-901	7	31
129	Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. <i>PLoS Pathogens</i> , <b>2011</b> , 7, e1002209	7.6	104
128	Does HAART efficacy translate to effectiveness? Evidence for a trial effect. <i>PLoS ONE</i> , <b>2011</b> , 6, e21824	3.7	13
127	Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. <i>American Journal of Epidemiology</i> , <b>2010</b> , 171, 198-205	3.8	73
126	Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 1100-7	5.1	43
125	Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 605-12	11.6	175
124	Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 875-81	1.6	36
123	Late presentation for human immunodeficiency virus care in the United States and Canada. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1512-20	11.6	165
122	The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. <i>PLoS Medicine</i> , <b>2010</b> , 7, e1000321	11.6	222
121	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1000890	7.6	219
120	HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. <i>Journal of Clinical Virology</i> , <b>2010</b> , 47, 18-22	14.5	11
119	Performance characteristics of the Cavidix ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. <i>Journal of Clinical Virology</i> , <b>2010</b> , 49, 198-204	14.5	13
118	Variability of the date of HIV diagnosis: a comparison of self-report, medical record, and HIV/AIDS surveillance data. <i>Annals of Epidemiology</i> , <b>2010</b> , 20, 734-42	6.4	8

117	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. <i>Lancet, The</i> , <b>2010</b> , 375, 396-407	40	240
116	Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 54, 515-23	3.1	22
115	How researchers define vulnerable populations in HIV/AIDS clinical trials. <i>AIDS and Behavior</i> , <b>2010</b> , 14, 1313-9	4.3	6
114	CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , <b>2010</b> , 7, 45	3	63
113	Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. <i>PLoS ONE</i> , <b>2010</b> , 5, e9390	3.7	123
112	Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. <i>PLoS ONE</i> , <b>2010</b> , 5, e11416	3.7	113
111	Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization. <i>Journal of Virology</i> , <b>2009</b> , 83, 4068-80	6.6	14
110	Treatment responses in antiretroviral treatment-naïve premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 473-6	11.6	20
109	Effect of pulmonary tuberculosis on mortality in patients receiving HAART. <i>Aids</i> , <b>2009</b> , 23, 707-15	3.5	32
108	Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. <i>PLoS Medicine</i> , <b>2009</b> , 6, e1000107	11.6	129
107	Social support and delays seeking care after HIV diagnosis, North Carolina, 2000-2006. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2009</b> , 21, 1148-56	2.2	18
106	Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2009</b> , 21, 1313-20	2.2	31
105	A novel codon insert in protease of clade B HIV type 1. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 547-50	1.6	4
104	Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 48, e47-9	11.6	18
103	Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2335-41	5.9	7
102	Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1582-90	11.6	51
101	Effect of early versus deferred antiretroviral therapy for HIV on survival. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1815-26	59.2	852
100	Sexually transmitted infections among patients with acute HIV in North Carolina. <i>Sexually Transmitted Diseases</i> , <b>2009</b> , 36, 372-4	2.4	14



99	Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 673-678	1.6	27
98	CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. <i>Nature Medicine</i> , <b>2008</b> , 14, 413-20	50.5	106
97	Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. <i>Journal of Virology</i> , <b>2008</b> , 82, 12449-63	6.6	452
96	Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 555-70	27.4	739
95	Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. <i>HIV Clinical Trials</i> , <b>2008</b> , 9, 11-25		8
94	Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197 Suppl 3, S261-71	7	12
93	Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. <i>Aids</i> , <b>2008</b> , 22, 1131-5	3.5	143
92	Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. <i>Psychosomatic Medicine</i> , <b>2008</b> , 70, 505-11	3.7	77
91	Smoking and predictors of pneumonia among HIV-infected patients receiving care in the HAART era. <i>Open Respiratory Medicine Journal</i> , <b>2008</b> , 2, 22-8	1.1	4
90	Emotional distress in African American women with HIV. <i>Journal of Prevention and Intervention in the Community</i> , <b>2007</b> , 33, 35-50	1.1	19
89	High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. <i>HIV Clinical Trials</i> , <b>2007</b> , 8, 193-204		14
88	Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 1360-5	1.6	6
87	Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 837-46	7	12
86	Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 749-54	11.6	32
85	Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , <b>2007</b> , 36, 294-301	7.8	139
84	Frequent detection of acute HIV infection in pregnant women. <i>Aids</i> , <b>2007</b> , 21, 2303-8	3.5	47
83	Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. <i>Aids</i> , <b>2007</b> , 21, 825-34	3.5	32
82	Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 2756-61	5.9	8

81	Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 623-32	7	79
80	Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2006</b> , 18 Suppl 1, S45-50	2.2	49
79	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. <i>Lancet, The</i> , <b>2006</b> , 368, 476-82	40	290
78	How clean was the KLEAN trial? [Authors' reply. <i>Lancet, The</i> , <b>2006</b> , 368, 1571	40	
77	Chagasic encephalitis as the initial manifestation of AIDS. <i>Annals of Internal Medicine</i> , <b>2006</b> , 144, 941-3	8	17
76	Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. <i>Aids</i> , <b>2006</b> , 20, 575-83	3.5	8
75	Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. <i>Aids</i> , <b>2006</b> , 20, 775-8	3.5	28
74	Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. <i>Aids</i> , <b>2006</b> , 20, 1591-5	3.5	37
73	Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. <i>Aids</i> , <b>2005</b> , 19, 1607-15	3.5	20
72	Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. <i>Kidney International</i> , <b>2005</b> , 67, 1526-31	9.9	136
71	Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. <i>Journal of Clinical Immunology</i> , <b>2005</b> , 25, 462-72	5.7	16
70	Detection of acute infections during HIV testing in North Carolina. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1873-83	59.2	317
69	Substance abuse and symptoms of mental illness among HIV-positive persons in the Southeast. <i>Southern Medical Journal</i> , <b>2005</b> , 98, 9-14	0.6	38
68	Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 116-23	5.9	42
67	Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV-positive patients: a 48-week randomized clinical trial. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 265-72	7	105
66	Brief but efficient: acute HIV infection and the sexual transmission of HIV. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1785-92	7	533
65	Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. <i>Aids</i> , <b>2004</b> , 18, 775-9	3.5	86
64	Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naïve patient. <i>Aids</i> , <b>2004</b> , 18, 1084-5	3.5	28

63	Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. <i>Journal of Virology</i> , <b>2004</b> , 78, 11208-18	6.6	101
62	A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 591-4	11.6	8
61	Frequent detection of acute primary HIV infection in men in Malawi. <i>Aids</i> , <b>2004</b> , 18, 517-24	3.5	101
60	Acute HIV revisited: new opportunities for treatment and prevention. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 113, 937-45	15.9	101
59	Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race. <i>Journal of Public Health Dentistry</i> , <b>2003</b> , 63, 86-91	1.6	40
58	Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2175-85	59.2	763
57	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 83-83	1.6	2
56	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 691-8	3.5	104
55	Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. <i>Aids</i> , <b>2003</b> , 17, 2345-9	3.5	43
54	Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. <i>Aids</i> , <b>2003</b> , 17, 2025-33	3.5	15
53	Novel therapies based on mechanisms of HIV-1 cell entry. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2228-38	59.2	208
52	A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 625-34	7	70
51	A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir. <i>Antiviral Therapy</i> , <b>2003</b> , 8, 507-518	1.6	6
50	Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2002</b> , 766, 307-17	3.2	10
49	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. <i>AIDS Research and Human Retroviruses</i> , <b>2002</b> , 18, 685-93	1.6	170
48	HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. <i>Journal of Immunology</i> , <b>2002</b> , 168, 2247-54	5.3	115
47	Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 169-80	27.4	129
46	Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1339-43	7	41

45	Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 35, 760-2	11.6	18
44	HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. <i>Aids</i> , <b>2002</b> , 16, 387-96	3.5	32
43	Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 288, 216-21	27.4	123
42	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , <b>2002</b> , 7, 271-281 <sup>6</sup>	1.6	9
41	Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. <i>Advances in Therapy</i> , <b>2001</b> , 18, 163-73	4.1	47
40	HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. <i>Aids</i> , <b>2001</b> , 15, 837-45	3.5	124
39	Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2001</b> , 45, 3663-8	5.9	19
38	Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 398-407	59.2	103
37	Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. <i>Aids</i> , <b>2001</b> , 15, 621-7	3.5	220
36	ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. <i>Aids</i> , <b>2001</b> , 15, F1-9	3.5	175
35	Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. <i>Aids</i> , <b>2000</b> , 14, 117-21	3.5	191
34	Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. <i>Aids</i> , <b>2000</b> , 14, 671-81	3.5	35
33	A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). <i>Aids</i> , <b>2000</b> , 14, 1601-10	3.5	65
32	Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. <i>Journal of Virology</i> , <b>2000</b> , 74, 8946-52	6.6	80
31	Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. <i>Aids</i> , <b>2000</b> , 14, 1553-61	3.5	17
30	Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1119-1119	5.9	4
29	Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 3025-9 <sup>5.9</sup>	5.9	36
28	Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 1817-26	5.9	136

27	Immune activation and plasma viral load in HIV-infected African individuals. <i>Aids</i> , <b>1999</b> , 13, 1283-5	3.5	2
26	Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg. <i>Annals of Pharmacotherapy</i> , <b>1999</b> , 33, 899-905	2.9	11
25	Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 1219-28	1.6	114
24	Sexual transmission of HIV: infectiousness and prevention. <i>Aids</i> , <b>1999</b> , 13, 155-66	3.5	129
23	Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. <i>Aids</i> , <b>1999</b> , 13, 1337-42	3.5	28
22	Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. <i>Aids</i> , <b>1999</b> , 13, 685-94	3.5	38
21	Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. <i>Journal of Clinical Microbiology</i> , <b>1999</b> , 37, 447-9	9.7	33
20	Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. <i>Journal of Virology</i> , <b>1999</b> , 73, 6271-81	6.6	165
19	Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual. <i>Aids</i> , <b>1999</b> , 13, 2171-3	3.5	22
18	Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. <i>Aids</i> , <b>1999</b> , 13, 2174-6	3.5	52
17	Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. <i>JAMA - Journal of the American Medical Association</i> , <b>1998</b> , 280, 35-41	27.4	182
16	Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. <i>Aids</i> , <b>1998</b> , 12, F181-9	3.5	132
15	Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 734-9	59.2	1610
14	Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. <i>Aids</i> , <b>1997</b> , 11, 169-75	3.5	21
13	A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 725-33	59.2	2231
12	Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. <i>Lancet, The</i> , <b>1997</b> , 349, 1868-73	40	690
11	Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. <i>Lancet, The</i> , <b>1996</b> , 348, 1547-51	40	68
10	Sensitive method for the detection of infectious HIV in semen of seropositive individuals. <i>Journal of Virological Methods</i> , <b>1996</b> , 56, 33-40	2.6	36

9	Quality control of HIV cultures in a clinical retrovirology laboratory. <i>Journal of Virological Methods</i> , <b>1996</b> , 58, 91-8	2.6	1
8	Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. <i>Journal of Virological Methods</i> , <b>1996</b> , 60, 161-70	2.6	98
7	Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 550-8	6.1	111
6	Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 1662-9	59.2	470
5	Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine. <i>Journal of Infectious Diseases</i> , <b>1993</b> , 168, 318-26	7	19
4	Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. <i>Nature</i> , <b>1993</b> , 361, 650-4	50.4	130
3	Maximizing sensitivity and specificity of PCR by pre-amplification heating. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 3749	20.1	267
2	New anti-HIV-1 therapies and combinations. <i>Aids</i> , <b>1990</b> , 4, S201	3.5	3
1	Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center		9